Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > AGN significant upside

<< Previous

Bullboard Posts

Next >>

Comment by TheBearInTheWoodson Aug 17, 2022 10:42pm

89 Views

Post# 34903880

RE:AGN significant upside

"Author has purchased Algernon shares on the open market and may choose to buy or sell at any time without notice. Author has been compensated for marketing services by Algernon Pharmaceuticals Inc."

Stockydoc wrote: This article from Medicalgold discusses AGN and why its improved fundamentals warrant a much higher valuation. Here's some details:

- AGN's strategy focuses on drug repurposing resulting in a lower risk of failure, reduced R&D costs, and a quicker time to market (6.5 yrs compared to 12-16 yrs)

- Discusses Ifenprodil which AGN is repurposing for idiopathic pulmonary fibrosis (IPF) and chronic cough

- Provides update on the phase 1 study for DMT in which researchers observed a statistically significant 40% increase in response to DMT treatment compared to control

- Lists upcoming catalysts including the pre-IND meeting for Phase 2b for Ifenprodil, attaining orphan drug designation for Ifenprodil, filing an application with the FDA for breakthrough therapy designation, and more

Looking at the technicals for AGN, shares were oversold in mid-July but have rebounded and could experience significant upside of 50-100% by the end of the year. AGN currently sits @ $4 (+10.50%) today.

https://www.medicalgold.ca/featured/algernon-human-clinical-trials-update